Nektar Therapeutics - NKTR STOCK NEWS

Nektar Therapeutics (NKTR) published preclinical data on NKTR-358 in the Journal of Translational Autoimmunity, showcasing its ability to selectively stimulate T regulatory (Treg) cell function for treating autoimmune disorders. The data indicated that NKTR-358 promotes sustained Treg expansion while minimizing T effector cell proliferation. Key findings included enhanced pharmacokinetics and efficacy in murine models of systemic lupus erythematosus (SLE). Continued clinical development is supported by ongoing Phase 2 studies conducted by Eli Lilly in various autoimmune conditions.

Nektar Therapeutics (NKTR) published pivotal preclinical data on NKTR-255, an IL-15 receptor agonist, in the Journal for ImmunoTherapy of Cancer. The data indicate NKTR-255 shows enhanced pharmacologic properties and superior anti-tumor efficacy compared to existing IL-15 agonists. This positions NKTR-255 favorably in its ongoing clinical trials for treating hematologic malignancies and solid tumors. The drug retains receptor binding like rhIL-15 while exhibiting reduced clearance and a longer half-life, supporting its therapeutic potential in immuno-oncology.

Nektar Therapeutics (NKTR) reported its financial results for Q1 2021, revealing a revenue decline to $23.6 million from $50.6 million in Q1 2020, primarily due to a previous milestone payment. Operating costs decreased to $133.0 million, significantly lower than $184.2 million the year prior, aided by reduced R&D expenses of $95.6 million. The net loss narrowed to $123.0 million or $0.68 per share, compared to $138.7 million or $0.78 per share in Q1 2020. The company continues advancing its clinical pipeline with ongoing studies for its lead drug, bempegaldesleukin, across various cancer indications.

Nektar Therapeutics (Nasdaq: NKTR) will disclose its financial results for Q1 2021 on May 6, 2021, post-market close. CEO Howard Robin will lead a conference call at 5:00 p.m. ET to discuss these results. Investors can access the press release and live audio webcast on the Nektar website. The conference call can be reached by dialing (877) 881-2183 for U.S. callers or (970) 315-0453 for international attendees, with a Conference ID of 9233368. The recorded webcast will be available for replay until May 27, 2021.

Nektar Therapeutics (NKTR) reported its financial results for Q4 and the full year 2020. Q4 revenue decreased to $23.5 million from $33.9 million in 2019, while annual revenue rose to $152.9 million, driven by $50 million in milestones from Bristol-Myers Squibb. Operating expenses totaled $134.2 million for Q4 and $578 million for the year, reflecting higher R&D costs despite a decrease in R&D expenses from 2019. The company reported a net loss of $117.2 million for Q4, and $444.4 million for the year. Nektar continues to advance its pipeline, notably with ongoing studies of bempegaldesleukin.

Nektar Therapeutics (NKTR) will announce its fourth quarter and annual financial results for 2020 on February 25, 2021, after U.S. markets close. A conference call hosted by President and CEO Howard Robin will begin at 5:00 p.m. ET. Investors can access the call via the company's website. Nektar specializes in biopharmaceuticals with a diverse portfolio in oncology, immunology, and virology. The results are highly anticipated as they will provide insights into the company's performance and future outlook.

Nektar Therapeutics (NASDAQ: NKTR) announced a collaboration with Merck for a Phase 2/3 clinical trial of bempegaldesleukin (BEMPEG) combined with KEYTRUDA® (pembrolizumab) in treating metastatic or unresectable recurrent squamous cell carcinoma of the head and neck. The study aims to enroll 500 patients and will assess overall response rate (ORR) and overall survival (OS). An interim analysis will be performed after 200 patients have been followed for at least four months. If successful, the trial will proceed to the Phase 3 stage.

Nektar Therapeutics (NKTR) announced a collaboration with SFJ Pharmaceuticals to advance the development of Bempegaldesleukin (BEMPEG) for treating head and neck cancer. SFJ will provide up to $150 million in funding for a Phase 2/3 clinical study involving BEMPEG and pembrolizumab in patients with PD-L1 expressing tumors. Nektar will sponsor the study and will make milestone payments to SFJ contingent on regulatory approvals. This partnership allows Nektar to expand its BEMPEG program without diluting shareholder equity, as highlighted by Howard Robin, President and CEO.

Nektar Therapeutics' President and CEO, Howard Robin, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on January 11, 2021, at 11:50 a.m. PT. This presentation will include a Q&A session accessible via a Webcast available on the Nektar Investor Events Calendar. Interested individuals can access the replay until February 10, 2021. Nektar, headquartered in San Francisco, focuses on developing investigational medicines in oncology, immunology, and virology, alongside a portfolio of approved partnered medicines.